• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint inhibitors in cancer immunotherapy.

作者信息

Himmel Megan E, Saibil Samuel D, Saltman Alexandra P

机构信息

Divisions of Rheumatology (Himmel, Saltman), Medical Oncology (Saibil) and Palliative Care (Saltman), Department of Medicine, University of Toronto, Toronto, Ont.

出版信息

CMAJ. 2020 Jun 15;192(24):E651. doi: 10.1503/cmaj.191231.

DOI:10.1503/cmaj.191231
PMID:32540906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7828839/
Abstract
摘要

相似文献

1
Immune checkpoint inhibitors in cancer immunotherapy.癌症免疫治疗中的免疫检查点抑制剂
CMAJ. 2020 Jun 15;192(24):E651. doi: 10.1503/cmaj.191231.
2
Development of Immunotherapy Combination Strategies in Cancer.癌症免疫疗法联合策略的发展。
Cancer Discov. 2021 Jun;11(6):1368-1397. doi: 10.1158/2159-8290.CD-20-1209. Epub 2021 Apr 2.
3
How to select cancer patients for immunotherapy.如何选择接受免疫治疗的癌症患者。
EBioMedicine. 2021 Jan;63:103184. doi: 10.1016/j.ebiom.2020.103184. Epub 2021 Jan 6.
4
Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?免疫基因特征：一种用于选择检查点抑制剂治疗患者的新工具？
Future Oncol. 2020 Jul;16(19):1327-1330. doi: 10.2217/fon-2020-0311. Epub 2020 May 12.
5
Immunotherapy in Older Adults With Cancer.老年癌症患者的免疫治疗
J Clin Oncol. 2021 Jul 1;39(19):2115-2127. doi: 10.1200/JCO.21.00138. Epub 2021 May 27.
6
Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.基于纳米颗粒的免疫原性细胞死亡诱导剂和免疫检查点抑制剂的联合癌症免疫疗法。
Int J Nanomedicine. 2021 Feb 22;16:1435-1456. doi: 10.2147/IJN.S285999. eCollection 2021.
7
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients.癌症患者免疫检查点阻断期间流感感染与疫苗接种的免疫学见解
Immunotherapy. 2020 Feb;12(2):105-110. doi: 10.2217/imt-2019-0200. Epub 2020 Feb 12.
8
Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.免疫佐剂、纳米颗粒和检查点抑制剂的癌症免疫疗法：免疫疗法治疗和跟踪反应的最新进展和挑战。
Pharmacol Ther. 2020 Mar;207:107456. doi: 10.1016/j.pharmthera.2019.107456. Epub 2019 Dec 19.
9
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.针对肿瘤微环境克服免疫检查点阻断治疗耐药性。
Immunol Lett. 2020 Apr;220:88-96. doi: 10.1016/j.imlet.2019.03.006. Epub 2019 Mar 15.
10
Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.预测免疫检查点抑制剂的获益可来自常规可测量的外周血参数。
Chin Clin Oncol. 2020 Apr;9(2):19. doi: 10.21037/cco.2020.03.03. Epub 2020 Apr 1.

引用本文的文献

1
High expression of SOX9 is a diagnostic and prognostic indicator of glioma.SOX9的高表达是胶质瘤的诊断和预后指标。
Front Oncol. 2025 Jul 7;15:1531937. doi: 10.3389/fonc.2025.1531937. eCollection 2025.
2
High Expression of RAB32 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioblastoma.RAB32高表达预示不良预后：胶质母细胞瘤的潜在治疗靶点
J Cancer. 2024 Oct 28;15(20):6710-6723. doi: 10.7150/jca.96162. eCollection 2024.
3
PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.PD-L1 调节 NF2 相关脑膜瘤中的肿瘤增殖和 T 细胞功能。
CNS Neurosci Ther. 2024 Jun;30(6):e14784. doi: 10.1111/cns.14784.
4
Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers.程序性细胞死亡蛋白1抑制剂联合奥沙利铂加S-1治疗Borrmann III型和IV型胃癌患者的安全性和有效性
World J Gastrointest Oncol. 2024 Apr 15;16(4):1281-1295. doi: 10.4251/wjgo.v16.i4.1281.
5
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
6
PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.PIK3CA突变驱动的免疫特征作为评估乳腺癌肿瘤免疫微环境和治疗反应的预后标志物。
J Cancer Res Clin Oncol. 2024 Mar 11;150(3):119. doi: 10.1007/s00432-024-05626-4.
7
Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.一种新型免疫原性细胞死亡相关特征的开发与验证，用于预测三阴性乳腺癌的预后和免疫浸润。
Cancer Rep (Hoboken). 2024 Mar;7(3):e2007. doi: 10.1002/cnr2.2007.
8
Shenling Baizhu Decoction (SLBZD) may play a synergistic role of tirelizumab in the treatment of colorectal cancer by influencing the imbalance of colon flora and Tumor microenvironment.参苓白术汤可能通过影响结肠菌群和肿瘤微环境的失衡，在替雷利珠单抗治疗结直肠癌中发挥协同作用。
J Cancer. 2024 Jan 1;15(1):30-40. doi: 10.7150/jca.88854. eCollection 2024.
9
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.纳米疫苗靶向淋巴结递呈用于癌症免疫治疗：最新进展和未来方向。
J Nanobiotechnology. 2023 Jul 7;21(1):212. doi: 10.1186/s12951-023-01977-1.
10
Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.免疫检查点抑制剂相关血栓形成：发生率、危险因素和管理。
Curr Oncol. 2023 Mar 4;30(3):3032-3046. doi: 10.3390/curroncol30030230.

本文引用的文献

1
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
2
Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.实体瘤治疗中免疫疗法的现状，以及未来的机遇与挑战。
Curr Oncol. 2018 Oct;25(5):e373-e384. doi: 10.3747/co.25.3840. Epub 2018 Oct 31.
3
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.